Biocytogen and Whitehawk partner to develop ADCs

PartnershipBispecific antibody-drug conjugates (BsADCs)Positive

AI Analysis

Summary

Biocytogen and Whitehawk Therapeutics announced a global partnership to develop bispecific antibody-drug conjugates (BsADCs). The collaboration combines expertise in antibody technology and conjugate therapeutics.

Importance:5/10

Sentiment:

0.30

partnershipADCbispecific_antibodiesdrug_development

Related Companies

$GBCYD

Read the original article

Published by Pharmaceutical Technology on July 8, 2026 7:59 AM

Read Original